Given a total leukocyte count of 45,400/µL with neutrophils 75%, lymphocytes 3%, myelocytes 2%, metamyelocytes 3%, band forms 16%, platelet count 185,000/µL, erythrocyte sedimentation rate 120 mm/hr, packed cell volume 22.9%, mean corpuscular volume 93.1 fL, and mean corpuscular hemoglobin concentration 36.6 g/dL, what is the interpretation?

Interpretation: Chronic Myeloid Leukemia (CML) in Chronic Phase

This blood picture is highly suggestive of Chronic Myeloid Leukemia (CML) in chronic phase, requiring immediate BCR-ABL1 testing (Philadelphia chromosome or molecular studies) for definitive diagnosis.

Key Diagnostic Features

The constellation of findings points strongly toward CML:

Leukocytosis with Left Shift

• Total WBC of 45,400/µL represents marked leukocytosis (normal ~4,000-11,000/µL)
• Presence of immature myeloid cells in peripheral blood is pathognomonic:
  • Myelocytes: 2%
  • Metamyelocytes: 3%
  • Band forms: 16%
• This "left shift of granulopoiesis" with circulating immature forms is characteristic of CML 1

Granulocytic Predominance

• Neutrophils at 75% with absolute neutrophilia
• Severe lymphopenia at 3% (normal ~20-40%) - this degree of relative lymphopenia is typical in CML where granulocytic expansion crowds out other lineages

Anemia with Inflammatory Features

• PCV 22.9% indicates moderate anemia (normal female ~36-44%, male ~40-50%)
• ESR 120 mm/hr is markedly elevated, reflecting the inflammatory/proliferative state
• MCV 93.1 fL is normocytic (normal 80-100 fL)
• MCHC 36.6 g/dL is at upper normal limit (normal 32-36 g/dL)

Platelet Count

• 185,000/µL is within normal range (150,000-450,000/µL), which is consistent with chronic phase CML 1

Diagnostic Criteria Alignment

According to ESMO/ELN guidelines, this presentation meets chronic phase CML criteria 1:

• Blast cells <15% in peripheral blood (not mentioned in your differential, suggesting <1%)
• Basophils <20% (not reported, likely normal)
• Platelets >100 × 10⁹/L (yours: 185,000/µL)
• Marked leukocytosis with left shift - classic presentation

Critical Next Steps

Immediate confirmatory testing required:

1. BCR-ABL1 molecular testing (RT-PCR) - most sensitive
2. Cytogenetic analysis for Philadelphia chromosome (t(9;22))
3. FISH testing if cytogenetics negative but clinical suspicion high
4. Bone marrow examination to assess blast percentage, fibrosis, and confirm phase

Important Caveats

• 5% of CML cases are Philadelphia chromosome-negative but BCR-ABL1 positive by molecular methods - these require FISH or RT-PCR for diagnosis 1
• If both Philadelphia and BCR-ABL1 are negative, this would represent atypical CML (a different disease entity requiring different management) 1
• The severe lymphopenia (3%) is notable - while CML causes relative lymphopenia, absolute counts this low warrant consideration of concurrent processes, though the overall picture remains most consistent with CML

Differential Considerations

While CML is most likely, the marked ESR elevation and anemia could suggest:

• Leukemoid reaction (but presence of myelocytes/metamyelocytes makes this less likely)
• Other myeloproliferative neoplasms (but the specific left shift pattern favors CML)
• Concurrent infection/inflammation (ESR 120 is very high even for CML alone)

The presence of circulating myelocytes and metamyelocytes in a patient with marked leukocytosis is essentially diagnostic of a myeloproliferative disorder, with CML being by far the most common cause requiring urgent molecular confirmation.